NovoCure Limited (NVCR) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $11.30. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is NVCR = $34 (+196.5% upside).
Valuation: NVCR trades at a trailing Price-to-Earnings (P/E) of -8.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.37.
Financials: revenue is $655M, +7.3%/yr average growth. Net income is $136M (loss), growing at -28.7%/yr. Net profit margin is -20.8% (negative). Gross margin is 74.5% (-4.1 pp trend).
Balance sheet: total debt is $290M against $340M equity (Debt-to-Equity (D/E) ratio 0.85, moderate). Current ratio is 2.9 (strong liquidity). Debt-to-assets is 36.1%. Total assets: $804M.
Analyst outlook: 9 / 15 analysts rate NVCR as buy (60%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 61/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
